Patents Assigned to Lidak Pharmaceuticals
  • Patent number: 5958765
    Abstract: A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro priming of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue of human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV F-protein .ltoreq.2.times.10.sup.-9 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.
    Type: Grant
    Filed: December 19, 1996
    Date of Patent: September 28, 1999
    Assignees: IDEC Pharmaceuticals Corporation, Lidak Pharmaceuticals
    Inventors: Peter Brams, Phillip R. Morrow
  • Patent number: 5948822
    Abstract: A method for treating a benign or malignant hyperproliferative skin lesion, comprising topically administering a C18 to C26 aliphatic alcohol to the skin lesion in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: September 7, 1999
    Assignee: Lidak Pharmaceuticals
    Inventors: Laura E. Pope, Mohammed H. Khalil, John F. Marcelletti, Lee R. Katz, David H. Katz
  • Patent number: 5698767
    Abstract: Laboratory non-human animals in which the immune system of a donor is induced in and thrives in vivo and expresses the immune response of the donor animal in a recipient non-human animal of a different species than the donor, and wherein malignant immune system cells of the donor can be induced in the recipient non-human animal by injection of non-malignant donor into the recipient are disclosed.
    Type: Grant
    Filed: October 16, 1995
    Date of Patent: December 16, 1997
    Assignee: Lidak Pharmaceuticals
    Inventors: Darcy B. Wilson, Donald E. Mosier
  • Patent number: 5534554
    Abstract: A stable, efficacious therapeutic cream wherein a principal therapeutic compounds are one or more C-20 to C-28 long chain aliphatic alcohols, of which n-docosanol is exemplary, comprising sucrose cocoate, sucrose stearates or sucrose distearate, or mixtures thereof, is disclosed.
    Type: Grant
    Filed: September 2, 1994
    Date of Patent: July 9, 1996
    Assignee: Lidak Pharmaceuticals
    Inventors: David H. Katz, Mohammed H. Khalil, John F. Marcelletti, Laura E. Pope, Lee R. Katz
  • Patent number: 5476996
    Abstract: Laboratory non-human animals in which the immune system of a human donor is induced in and thrives in vivo and expresses the immune response of the human donor in a recipient non-human animal, and wherein malignant immune system cells of the human donor can be induced in the recipient non-human animal by injection of non-malignant donor cells into the recipient are disclosed.
    Type: Grant
    Filed: May 4, 1993
    Date of Patent: December 19, 1995
    Assignee: Lidak Pharmaceuticals
    Inventors: Darcy B. Wilson, Donald E. Mosier
  • Patent number: 5470714
    Abstract: A one reaction step method for determining hydrophobic analytes, such as free hydrophobic analytes, comprising the steps of mixing a solution suspected of containing the hydrophobic analyte, e.g. free fatty acid, with a reagent comprising a fluorescently modified specific-binding protein for the hydrophobic analyte, detecting a fluorescence difference between the fluorescently modified specific-binding protein in the bound and unbound condition, and relating said fluorescence difference to the amount of arialyre in the solution is disclosed.
    Type: Grant
    Filed: November 24, 1993
    Date of Patent: November 28, 1995
    Assignee: Lidak Pharmaceuticals
    Inventor: Alan M. Kleinfeld
  • Patent number: 5166219
    Abstract: A method of arthritis and other inflammatory diseases in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal to be treated a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier is disclosed.
    Type: Grant
    Filed: July 29, 1991
    Date of Patent: November 24, 1992
    Assignee: Lidak Pharmaceuticals
    Inventor: David H. Katz
  • Patent number: 5071879
    Abstract: Systemic antiviral treatment using a narrow class of aliphatic straight-chain saturated monohydric alcohols which have from 20 to 26, preferably 22 to 26, carbons in the chain in physiologically compatible compositions for injection or trans-mucus membrane introduction into humans and other animals is disclosed.
    Type: Grant
    Filed: November 2, 1989
    Date of Patent: December 10, 1991
    Assignee: Lidak Pharmaceuticals
    Inventor: David H. Katz
  • Patent number: 5070107
    Abstract: Systemic antiviral treatment using a narrow class of aliphatic straight-chain saturated monohydric alcohols which have from 27 to 32 carbons in the chain in physiologically compatible compositions for injection or trans-mucus membrance introduction into humans and other mammals is disclosed.
    Type: Grant
    Filed: November 2, 1989
    Date of Patent: December 3, 1991
    Assignee: Lidak Pharmaceuticals
    Inventor: David H. Katz